Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Protective Effects of D-Penicillamine on Catecholamine-Induced Myocardial Injury

M. Říha, P. Hašková, J. Martin, T. Filipský, K. Váňová, J. Vávrová, M. Holečková, P. Homola, L. Vítek, V. Palicka, T. Šimůnek, P. Mladěnka,

. 2016 ; 2016 (-) : 5213532. [pub] 20151214

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc17000617

Iron and copper release participates in the myocardial injury under ischemic conditions and hence protection might be achieved by iron chelators. Data on copper chelation are, however, sparse. The effect of the clinically used copper chelator D-penicillamine in the catecholamine model of acute myocardial injury was tested in cardiomyoblast cell line H9c2 and in Wistar Han rats. D-Penicillamine had a protective effect against catecholamine-induced injury both in vitro and in vivo. It protected H9c2 cells against the catecholamine-induced viability loss in a dose-dependent manner. In animals, both intravenous D-penicillamine doses of 11 (low) and 44 mg/kg (high) decreased the mortality caused by s.c. isoprenaline (100 mg/kg) from 36% to 14% and 22%, respectively. However, whereas the low D-penicillamine dose decreased the release of cardiac troponin T (specific marker of myocardial injury), the high dose resulted in an increase. Interestingly, the high dose led to a marked elevation in plasma vitamin C. This might be related to potentiation of oxidative stress, as suggested by additional in vitro experiments with D-penicillamine (iron reduction and the Fenton reaction). In conclusion, D-penicillamine has protective potential against catecholamine-induced cardiotoxicity; however the optimal dose selection seems to be crucial for further application.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000617
003      
CZ-PrNML
005      
20170119112831.0
007      
ta
008      
170103s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1155/2016/5213532 $2 doi
024    7_
$a 10.1155/2016/5213532 $2 doi
035    __
$a (PubMed)26788248
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Říha, Michal $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.
245    10
$a Protective Effects of D-Penicillamine on Catecholamine-Induced Myocardial Injury / $c M. Říha, P. Hašková, J. Martin, T. Filipský, K. Váňová, J. Vávrová, M. Holečková, P. Homola, L. Vítek, V. Palicka, T. Šimůnek, P. Mladěnka,
520    9_
$a Iron and copper release participates in the myocardial injury under ischemic conditions and hence protection might be achieved by iron chelators. Data on copper chelation are, however, sparse. The effect of the clinically used copper chelator D-penicillamine in the catecholamine model of acute myocardial injury was tested in cardiomyoblast cell line H9c2 and in Wistar Han rats. D-Penicillamine had a protective effect against catecholamine-induced injury both in vitro and in vivo. It protected H9c2 cells against the catecholamine-induced viability loss in a dose-dependent manner. In animals, both intravenous D-penicillamine doses of 11 (low) and 44 mg/kg (high) decreased the mortality caused by s.c. isoprenaline (100 mg/kg) from 36% to 14% and 22%, respectively. However, whereas the low D-penicillamine dose decreased the release of cardiac troponin T (specific marker of myocardial injury), the high dose resulted in an increase. Interestingly, the high dose led to a marked elevation in plasma vitamin C. This might be related to potentiation of oxidative stress, as suggested by additional in vitro experiments with D-penicillamine (iron reduction and the Fenton reaction). In conclusion, D-penicillamine has protective potential against catecholamine-induced cardiotoxicity; however the optimal dose selection seems to be crucial for further application.
650    _2
$a zvířata $7 D000818
650    _2
$a kardiotonika $x chemie $x farmakologie $7 D002316
650    _2
$a katecholaminy $7 D002395
650    _2
$a buněčné linie $7 D002460
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a deferoxamin $x farmakologie $7 D003676
650    _2
$a koncentrace vodíkových iontů $7 D006863
650    _2
$a ionty $7 D007477
650    _2
$a železo $x metabolismus $7 D007501
650    _2
$a chelátory železa $x farmakologie $7 D007502
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myokard $x patologie $7 D009206
650    _2
$a penicilamin $x chemie $x farmakologie $7 D010396
650    _2
$a potkani Wistar $7 D017208
650    _2
$a troponin T $x metabolismus $7 D020107
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hašková, Pavlína $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.
700    1_
$a Martin, Jan $u Department of Pharmacognosy, Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.
700    1_
$a Filipský, Tomáš $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.
700    1_
$a Váňová, Kateřina $u Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University in Prague, Kateřinská 1660/32, 121 08 Prague, Czech Republic.
700    1_
$a Vávrová, Jaroslava $u Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Charles University in Prague, Sokolská 581, 500 05 Hradec Králové, Czech Republic.
700    1_
$a Holečková, Magdalena $u Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Charles University in Prague, Sokolská 581, 500 05 Hradec Králové, Czech Republic.
700    1_
$a Homola, Pavel $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.
700    1_
$a Vítek, Libor $u Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University in Prague, Kateřinská 1660/32, 121 08 Prague, Czech Republic; 4th Department of Internal Medicine, 1st Faculty of Medicine, Charles University in Prague, U Nemocnice 2, 128 02 Prague, Czech Republic.
700    1_
$a Palicka, Vladimír $u Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Charles University in Prague, Sokolská 581, 500 05 Hradec Králové, Czech Republic.
700    1_
$a Šimůnek, Tomáš $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.
700    1_
$a Mladěnka, Přemysl $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.
773    0_
$w MED00180520 $t Oxidative medicine and cellular longevity $x 1942-0994 $g Roč. 2016, č. - (2016), s. 5213532
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26788248 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20170119112940 $b ABA008
999    __
$a ok $b bmc $g 1179757 $s 961184
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 2016 $c - $d 5213532 $e 20151214 $i 1942-0994 $m Oxidative medicine and cellular longevity $n Oxid Med Cell Longev $x MED00180520
LZP    __
$a Pubmed-20170103

Najít záznam

Citační ukazatele

Možnosti archivace